PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy

被引：0

作者：

Yixiang Zhu

Ye Zhang

Xingsheng Hu

Mingzhao Wang

Hongyu Wang

Yutao Liu

机构：

[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology

[2] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Radiation Oncology

[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,undefined

[4] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷

关键词：

EGFR mutation or ALK rearrangement; Brain metastasis; Immune checkpoint inhibitor (ICI); Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：3557 / 3566

页数：9

共 50 条

[21] Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC
Song, Lianxi
Xu, Qinqin
Lizaso, Analyn
Zhang, Yongchang
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 349 - 351
[22] Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK plus non-small cell lung cancer (NSCLC)
Weickhardt, Andrew James
Scheier, Benjamin
Burke, Joseph Malachy
Gan, Gregory
Doebele, Robert Charles
Bunn, Paul A.
Gaspar, Laurie E.
Kavanagh, Brian D.
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[23] Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
Hong, Shaodong
Chen, Nan
Fang, Wenfeng
Zhan, Jianhua
Liu, Qing
Kang, Shiyang
He, Xiaobo
Liu, Lin
Zhou, Ting
Huang, Jiaxing
Chen, Ying
Qin, Tao
Zhang, Yaxiong
Ma, Yuxiang
Yang, Yunpeng
Zhao, Yuanyuan
Huang, Yan
Zhang, Li
ONCOIMMUNOLOGY, 2016, 5 (03):
[24] Rh-endostatin Combined With PD-1 inhibitors as Firstline Treatment for EGFR/ALK-Negative, Nonsquamous NSCLC
Wang, D.
Feng, Y.
Wang, H.
Peng, H.
Zhang, W.
Su, W.
Li, H.
Hu, B.
Bai, Y.
Ma, H.
Huang, L.
Zhu, T.
Qian, H.
Li, Y.
Fang, X.
Ren, B.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S618 - S618
[25] EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases
Jiang, Tao
Su, Chunxia
Li, Xuefei
Zhao, Chao
Zhou, Fei
Ren, Shengxiang
Zhou, Caicun
Zhang, Jun
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : 1718 - 1728
[26] Brain Metastases in EGFR- and ALK-Positive NSCLC : Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation
Thomas, Nicholas J.
Myall, Nathaniel J.
Sun, Fangdi
Patil, Tejas
Mushtaq, Rao
Yu, Chandler
Sinha, Sumi
Pollom, Erqi L.
Nagpal, Seema
Camidge, D. Ross
Rusthoven, Chad G.
Braunstein, Steve E.
Wakelee, Heather A.
McCoach, Caroline E.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 116 - 129
[27] Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib
Abraham, Jame
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2016, 14 (06): : 241 - 243
[28] Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
Ou, S. -H. I.
Jaenne, P. A.
Bartlett, C. H.
Tang, Y.
Kim, D. -W.
Otterson, G. A.
Crino, L.
Selaru, P.
Cohen, D. P.
Clark, J. W.
Riely, G. J.
ANNALS OF ONCOLOGY, 2014, 25 (02) : 415 - 422
[29] Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
Leduc, C.
Besse, B.
ANNALS OF ONCOLOGY, 2014, 25 (10) : 2092 - 2092
[30] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
Jiang, T.
Zhou, C.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →